Edition:
United States

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

17.15USD
24 Mar 2017
Change (% chg)

$0.20 (+1.18%)
Prev Close
$16.95
Open
$16.90
Day's High
$17.42
Day's Low
$16.90
Volume
48,796
Avg. Vol
103,248
52-wk High
$17.45
52-wk Low
$7.03

Latest Key Developments (Source: Significant Developments)

Epizyme qtrly loss per share $0.60
Thursday, 9 Mar 2017 06:32am EST 

Epizyme Inc : Epizyme reports 2016 financial results and provides 2017 pipeline goals . Qtrly loss per share $0.60 .Epizyme-Believes cash,cash equivalents,marketable securities of $242.2 million as of dec31, will be sufficient to fund planned operations into at least q3 2018.  Full Article

Epizyme receives positive written response from FDA allowing enrollment of patients with follicular lymphoma in U.S.
Thursday, 19 Jan 2017 08:55am EST 

Epizyme Inc : Epizyme Inc - received a positive written response from FDA allowing enrollment of patients with follicular lymphoma in U.S. .Epizyme- Response allowing enrollment as part of global phase 2 study of tazemetostat as treatment for relapsed/refractory non-hodgkin lymphoma - sec filing.  Full Article

Epizyme reported Q2 EPS ($0.49)
Monday, 8 Aug 2016 06:30am EDT 

Epizyme Inc : Epizyme announces second quarter 2016 financial results and progress against corporate objectives . Qtrly loss per share $0.49 . Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S .Believes cash, cash equivalents as of June 30, 2016 will be sufficient to fund company's planned operations into at least Q2 of 2018.  Full Article

Epizyme to work with Lymphoma Study Association
Monday, 9 May 2016 06:40am EDT 

Epizyme Inc : Epizyme announces collaboration with Lymphoma Study Association to evaluate combination of Tazemetostat with R-Chop in front-line Non-Hodgkin Lymphoma . Phase 1B/2 trial will be jointly conducted with Lymphoma Academic Research Organisation (LYSARC), operational arm of LYSA . Company has announced plans to initiate additional clinical evaluations of Tazemetostat in 2016 . Open-Label, clinical study will be sponsored by LYSARC and conducted at multiple sites in france .Epizyme and LYSARC jointly designed study, which is expected to begin enrolling patients mid-year.  Full Article

Epizyme Announces Proposed Public Offering of Common Stock
Tuesday, 5 Jan 2016 04:01pm EST 

Epizyme Inc :Announces proposed public offering of common stock.Says intends to offer and sell up to $120,000,000 of shares of its common stock in an underwritten public offering.Says intends to grant the underwriters a 30-day option to purchase up to an additional $18 million of shares of its common stock.Says intends to use the net proceeds to fund the global development costs of tazemetostat, epizyme's novel oral ezh2 inhibitor.  Full Article

Epizyme Inc says FDA acceptance of IND application for tazemetostat in diffuse large B-cell lymphoma
Monday, 28 Dec 2015 08:00am EST 

Epizyme Inc:Says FDA acceptance of IND application for tazemetostat in diffuse large B-cell lymphoma.IND acceptance will allow the company to enroll DLBCL patients in the United States into this ongoing trial.In first half of 2016, Co also plans to initiate additional clinical evaluations of tazemetostat, including a combination study with R-CHOP in front-line, high-risk patients with DLBCL, and a combination study with a B-cell signaling agent or immuno-oncology agent in B-cell NHL.Expects to present interim data from the phase 2 study in NHL at a medical conference in mid-2016.  Full Article

Epizyme appoints Robert Bazemore President and Chief Executive Officer
Wednesday, 5 Aug 2015 04:10pm EDT 

Epizyme Inc:Appoints robert bazemore president and chief executive officer.Says robert bazemore will succeed robert gould.Says transition effective September 10, 2015.Says outgoing president and CEO Robert Gould, will continue to serve as member of board of directors.  Full Article

Epizyme announces extension of Celgene Research Collaboration
Thursday, 9 Jul 2015 07:00am EDT 

Epizyme:Announces extension of Celgene research collaboration.Says Epizyme to receive $10 million extension fee payment and up to $610 million in potential milestones.Says Epizyme extends cash runway through at least the end of the second quarter of 2017.Says Celgene will have option to license histone methyltransferase (hmt) inhibitors being developed by Epizyme against 3 predefined targets.Says Epizyme will be responsible for leading and funding development for each target candidate through phase 1 clinical trials.Says Epizyme also may earn a royalty of up to a low double-digit percentage on worldwide net sales for two of the product candidates.Says if Celgene chooses to continue its license for a specific target, it may do so by making an additional pre-specified payment.  Full Article

Epizyme Inc announces additional positive data from ongoing phase 1 study of tazemetostat (EPZ-6438) in relapsed or refractory non-hodgkin lymphom
Sunday, 21 Jun 2015 04:40am EDT 

Epizyme Inc:Announces results from ongoing phase 1 trial of tazemetostat (EPZ-6438), a first-in-class EZH2 inhibitor, showing meaningful clinical activity when used as an oral monotherapy in patients with advanced B-cell non-Hodgkin lymphomas (NHL) and solid tumors.Says in NHL, treatment with tazemetostat continues to demonstrate an encouraging profile with nine of 15 evaluable NHL patients achieving an objective response, including a partial response in the first treated patient with an EZH2 tumor mutation.  Full Article

Epizyme Inc announces closing of common stock offering
Friday, 17 Apr 2015 04:30pm EDT 

Epizyme Inc:Says that underwriters for recently completed underwritten public offering of common stock have partially exercised their option to purchase additional shares of common stock from Epizyme.Underwriters purchased 701,448 shares from Epizyme at public offering price of $20.75 per share, less underwriting discounts.Aggregate net proceeds before expenses to Epizyme from offering are about $130.7 mln, after deducting underwriting discounts and commissions.Leerink Partners LLC, Cowen and Company, LLC and RBC Capital Markets, LLC served as joint book-running managers for offering.JMP Securities LLC served as lead manager for offering.SunTrust Robinson Humphrey, Inc. and Mizuho Securities USA Inc. were co-managers for offering.  Full Article

More From Around the Web

BRIEF-Epizyme qtrly loss per share $0.60

* Epizyme reports 2016 financial results and provides 2017 pipeline goals